Intervention

LY3537982

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting1

Common conditions7

Lead sponsors shown1

Clinical trials

2 shown

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21

RECRUITING

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640 · 2021-07-19

ACTIVE_NOT_RECRUITING

Common conditions

Carcinoma, Non-Small-Cell Lung2 Biliary Tract Neoplasms1 Colorectal Neoplasms1 Endometrial Neoplasms1 Neoplasm Metastasis1 Ovarian Neoplasms1 Pancreatic Neoplasms1

Leading sponsors

Eli Lilly and Company 2

Trial status mix

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

PHASE11

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.